Larry Lasky is currently a general partner at Latterell Venture Partners, a life science-based venture capital partnership. He has founded several companies and currently sits on a number of boards including Proteolix, Oncomed, Bioverdant, Tetralogic and Cell Biosciences. Before becoming a v.c., he spent 20 years as a scientist at Genentech working in various fields including vaccines, inflammation, cellular signaling and anti-tumor monoclonal antibody production. Two of his projects, vaccines for herpes simplex virus and HIV, went into phase 3 clinical trials. During his time at Genentech, he was a standing member of the research review committee, which had oversight over all of research, and he retired as the Genentech Fellow, the highest scientific position at the company. Before Genentech, he was a founding scientist of the Genetics Institute, one of the earliest biotechnology companies. He received his B.A. and PhD in molecular biology from UCLA and did his postdoctoral studies at CalTech.

MOT Course(s):

• ENTREPRENEURSHIP IN BIOTECHNOLOGY

Latterell Venture Partners